![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 45, 42769-42774, November 8, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Schering-Plough Research Institute,
Kenilworth, New Jersey 07033
Received for publication, July 10, 2002, and in revised form, August 15, 2002
Nrf2, a basic leucine zipper transcription
factor, is an essential activator of the coordinated transcription of
genes encoding antioxidant enzymes and phase II detoxifying enzymes
through the regulatory sequence termed antioxidant response element
(ARE). Recently we reported evidence for the involvement of protein
kinase C (PKC) in phosphorylating Nrf2 and triggering its
nuclear translocation in response to oxidative stress. We show here
that phosphorylation of purified rat Nrf2 by the catalytic
subunit of PKC was blocked by a synthetic peptide mimicking one of the
potential PKC sites. Accordingly, Nrf2 bearing a Ser to Ala
mutation at amino acid 40 (S40A) could not be phosphorylated by PKC.
The S40A mutation did not affect in vitro binding of
Nrf2/MafK to the ARE. However, it partially impaired Nrf2
activation of ARE-driven transcription in a reporter gene assay when
Keap1 was overexpressed. In vitro transcribed/translated
Keap1 could be coimmunoprecipitated with Nrf2. Phosphorylation
of wild-type Nrf2 by PKC promoted its dissociation from Keap1,
whereas the Nrf2-S40A mutant remained associated. These findings
together with our prior studies suggest that the PKC-catalyzed
phosphorylation of Nrf2 at Ser-40 is a critical signaling event
leading to ARE-mediated cellular antioxidant response.
The antioxidant response element
(ARE)1 is a regulatory
sequence involved in the coordinated transcriptional activation of genes coding for a number of antioxidant enzymes and phase II detoxifying enzymes (1-6). Reactive oxygen species and electrophiles are potent activators of genes containing an ARE, mediated by the basic
leucine zipper (bZIP) transcription factor Nrf2 (NF-E2-related factor 2) (7-9). Accumulated evidence from studies of
nrf2-null mice has established that Nrf2 is an
essential ARE-binding factor involved in both constitutive and
inducible gene expression via the ARE (9-11). An important regulatory
step leading to ARE activation is the oxidative stress-induced nuclear
translocation of Nrf2, which normally appears to be sequestered
in the cytoplasm by the cytoskeleton-binding Keap1 protein (12-14).
However, the precise mechanism by which ARE-activating signals reach
Nrf2 and cause dissociation of the putative inhibitory
Nrf2-Keap1 complex remains unclear.
Several protein kinase pathways have been implicated in transducing
oxidative stress signals to gene expression mediated through the ARE. A
number of reports have addressed a possible role for extracellular
signal-regulated kinase (ERK1/2) in ARE activation. The findings have
however remained controversial: ERK1/2 has been found to regulate the
ARE positively in certain hepatoma cells (15-17) but negatively in
others (18). Similarly, p38 MAP (mitogen-activated protein) kinase
has also been shown to affect ARE activity, either positively (17, 19,
20) or negatively (16, 21). More recently, phosphatidylinositol
3-kinase and its downstream target Akt/PKB (protein kinase B) have been
linked to activation of the ARE in hepatoma (18, 19) and neuroblastoma
(22) cell lines. However, none of the known cellular components
involved in ARE regulation have been shown to be targets of any of
these kinases.
Recently, we reported several findings that indicate an important role
for protein kinase C (PKC) in the ARE-mediated gene expression (23). 1)
Phorbol 12-myristate 13-acetate (PMA), a potent PKC-activating phorbol
ester, stimulates ARE-driven transcription, which is blocked by
selective PKC inhibitors. 2) Nuclear translocation of Nrf2 is
induced by PMA but arrested by PKC inhibitors. 3) Both Nrf2
nuclear translocation and activation of the ARE by
tert-butylhydroquinone (tBHQ) treatment are suppressed by
PKC inhibitors. 4) Nrf2 is phosphorylated in vitro by
purified PKC or immunoprecipitated PKC from tBHQ-induced cells. 5)
Nrf2 phosphorylation in HepG2 cells is enhanced by PMA and tBHQ
but abolished by PKC inhibitors. Together these results suggest that
one critical step in the signaling cascade toward ARE activation may be
the phosphorylation of Nrf2 by PKC, which promotes the nuclear
translocation of this transcription factor in response to oxidative
stress. The present study is a continuation of our investigation into
the involvement of PKC in regulating the ARE. We sought to identify the
site of phosphorylation in Nrf2 by PKC and to characterize the
mechanistic significance of Nrf2 phosphorylation.
Purification of Nrf2--
A high level expression plasmid
of rat Nrf2 gene linked at its N terminus to a His6
tag was obtained by cloning the rat Nrf2 cDNA
(GenBankTM accession number AF037350) into the pQE-30
vector (Qiagen). S40A mutant (AGT Kinase Assays--
Purified His6-tagged rat
Nrf2 wild-type and S40A mutant proteins were used as substrates
in in vitro kinase assays with catalytic subunits of rat
brain PKC (Calbiochem). 50-µl reactions were carried out at 30 °C
in a buffer containing 25 mM HEPES (pH 7.5), 10 mM MgCl2, 200 µM ATP, and 2 µCi
of [ EMSA--
EMSAs were performed essentially as described
previously (24). A double-stranded oligonucleotide containing the rat
QR gene ARE was used as probe after end-labeling with
[ Cell Culture, Transfection, and Reporter Assays--
HepG2 cells
were obtained from the American Type Culture Collection and maintained
as previously described (1). Transient transfection was performed as
before on cells in 6-well plates at ~70% confluency using
LipofectAMINE Plus reagent (Invitrogen). 1 µg of an expression
plasmid containing rat QR ARE linked to chloramphenicol
acetyltransferase (CAT) reporter gene was co-transfected with 0.12 µg
of pcDNA3 plasmid (Invitrogen) bearing wild-type or S40A mutant
Nrf2 and, where indicated, with 60 ng of pcDNA3 plasmid
containing rat Keap1 (GenBankTM accession number AF304364).
Total amount of transfected DNA was kept constant at 2 µg by the
addition of pcDNA3 vector to the DNA mixture. Cells were incubated
for 18 h after overnight recovery from transfection and harvested
in M-PER mammalian protein extraction reagent (Pierce). Cell lysates
were assayed for CAT activity as described (23), and the results were
quantitated by a PhosphorImager.
In Vitro Association Assays--
In vitro
transcription/translation of the pcDNA3 plasmids bearing
Nrf2 and Keap1 was carried out using the TNT coupled
wheat germ extract system (Promega) in the presence of
[35S]methionine according to the manufacturer's
instructions. The products were then incubated together for 15 min at
30 °C before immunoprecipitation by an anti-Nrf2 antibody in
an immunoprecipitation buffer containing 50 mM Tris (pH
8.0), 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate,
0.1% SDS for 4 h at 4 °C, followed by the addition of protein
A-Trisacryl beads (Pierce). The mixture was rotated at 4 °C for
1 h and washed extensively in immunoprecipitation buffer
containing 0.3 M NaCl. Precipitates were resolved by
SDS-PAGE and detected by autoradiography. Quantitation of band
intensity was performed on a PhosphorImager. To determine the effect of PKC phosphorylation on Nrf2-Keap1 interaction, an equal amount of labeled Nrf2 wild-type or S40A mutant was incubated with PKC and Keap1 in kinase assay buffer for 30 min at 30 °C before immunoprecipitation.
A Peptide Inhibitor of Nrf2 Phosphorylation by PKC--
In
prior studies we showed that Nrf2 is phosphorylated in HepG2
cells (23). Nrf2 phosphorylation was activated by the phorbol ester PMA but was blocked by the PKC inhibitor staurosporine, suggesting that Nrf2 may be a PKC target. Accordingly, in
vitro PKC assays revealed that purified rat Nrf2 was
phosphorylated by the catalytic subunit of rat brain PKC or by PKC
immunoprecipitated from HepG2 lysates. To identify the specific site(s)
of phosphorylation in Nrf2 by PKC, a serine/threonine kinase,
synthetic peptides mimicking potential Nrf2 PKC sites were used
as competitors for in vitro phosphorylation of Nrf2
by PKC. Rat Nrf2 is a 597-amino acid residue protein containing
seven potential PKC phosphorylation sites according to the canonical
pattern (S/T)X(R/K), where X is any residue. Six
8-residue peptides (36-43, 375-382, 414-421, 435-442, 585-592,
590-597) were synthesized corresponding to potential PKC target sites
at Ser-40, Ser-378, Thr-417, Thr-418, Ser-439, Ser-589, and Thr-594,
respectively (Fig. 1A). All
were readily soluble in 20% Me2SO except peptide 36-43,
whose solubility was greatly improved when it was extended at both ends
by one residue to a 10-mer (EVFDFSQRQK). In vitro kinase
assays were performed as described previously (23) using commercially
obtained catalytic subunits of rat brain PKC and purified rat
Nrf2 as substrate. Although Nrf2 phosphorylation by PKC
appeared unaffected or even enhanced by several of the peptides, it was
reduced by more than 90% in the presence of 5 mM peptide
35-44 (Fig. 1B). PKC activity against a standard substrate
was not suppressed by this peptide (not shown), indicating that its
effect was not on the enzyme itself. These findings suggest that Ser-40
of Nrf2 is an authentic site of phosphorylation by PKC.
A Nrf2 Mutant Defective for PKC Phosphorylation--
To
confirm these peptidomimetic data a site-directed mutagenesis approach
was utilized. Rat Nrf2 gene bearing a AGT
It should be noted that Ser-40 is also one of four potential PKC sites
in human Nrf2 (GenBankTM accession number Q16236),
which is highly homologous to the rat Nrf2. It is likely that
PKC phosphorylates human Nrf2 at the same site and that the
phosphorylation of Nrf2 observed in human hepatoma HepG2 cells
(23) is at least in part catalyzed by PKC on Ser-40.
Binding of Nrf2/MafK Complex to the ARE Is
Independent of PKC--
We and others have previously shown that
in vitro transcribed/translated Nrf2 binds with high
affinity to the ARE as part of a heterodimeric complex with small Maf
proteins (9, 24, 25). To examine whether interaction of Nrf2
with the ARE is affected by the mutation abolishing PKC
phosphorylation, in vitro EMSAs with E. coli-expressed His6-Nrf2-S40A and in
vitro translated MafK were performed, using ARE sequence derived
from the rat QR gene as probe. As expected, Nrf2
(wild-type or S40A) or MafK alone could not bind to the ARE. In the
presence of MafK, however, both Nrf2-WT and Nrf2-S40A
formed shifted complexes with the ARE probe. These complexes were
supershifted upon incubation with an antibody against Nrf2 (Fig.
4A). The intensity and
mobility of the wild-type and S40A mutant complexes are virtually
indistinguishable. Furthermore, formation of both types of complexes
was completely blocked by excess unlabeled QR ARE but not by
random oligonucleotides (Fig. 4B). Therefore the S40A
mutation did not alter the specific high affinity interaction between
Nrf2/MafK and the ARE. Indeed, PKC-phosphorylated Nrf2
bound to the ARE in a similar manner as non-phosphorylated wild-type
Nrf2 or the S40A mutant defective for PKC phosphorylation (Fig.
4C). Thus the formation of ARE-binding transcriptional
complex containing Nrf2 and small Maf proteins does not appear
to be regulated by the phosphorylation of Nrf2 by PKC.
Keap1 Is Involved in the Impaired ARE Activation by
Nrf2-S40A--
To determine whether the Nrf2-S40A mutant
has an effect on Nrf2 transactivation of the ARE, we conducted
transient transfection experiments in HepG2 cells. Introduction of
Nrf2-overexpressing plasmid into a number of hepatoma cell lines
has previously been shown to result in dose-dependent
activation of the ARE-mediated transcription (16, 24). A rat
QR ARE-linked CAT reporter gene was co-transfected with a
high copy plasmid vector bearing wild-type Nrf2. An ~12-fold
activation of ARE-driven CAT activity was observed using 0.12 µg of
Nrf2 plasmid DNA. Co-transfection with an equal amount of
Nrf2-S40A resulted in comparable levels of activation (Fig.
5).
Because Keap1 has been shown to repress Nrf2 activity by
sequestering it in the cytoplasm (12), we asked if any functional defect of the Nrf2-S40A mutant might involve Keap1. As expected, co-transfection of Keap1 with wild-type Nrf2 decreased
Nrf2-dependent ARE activation. Interestingly,
overexpression of Keap1 resulted in a partial impairment of ARE
activation by the Nrf2-S40A mutant that was not seen with
endogenous levels of Keap1 in HepG2 cells. ARE activation by
Nrf2-S40A was reduced to a level less than 50% of that achieved
with wild-type Nrf2, from an ~6-fold activation to 2.5-fold
(Fig. 5). In these transfected cells, Nrf2 wild-type and S40A
proteins were expressed to comparable levels as verified by Western
blot using an anti-Nrf2 antibody (not shown). These findings
indicate a role for Keap1 in the apparent transactivation defect
exhibited by the Nrf2-S40A mutant.
Phosphorylation of Nrf2 by PKC Promotes Its Dissociation
from Keap1--
Studies from Itoh et al. (12) have shown
that Nrf2 interacts with Keap1 through a region of about 100 amino acid residues at its N terminus (named Neh2 domain). Because PKC
phosphorylates Nrf2 at Ser-40, we explored whether the
Keap1-dependent deficiency of the S40A mutant in ARE
activation is attributable to its altered interaction with Keap1. We
first tested if in vitro transcribed/translated Nrf2
and Keap1 proteins could associate with each other. Nrf2 and
Keap1 were labeled in the presence of [35S]methionine
during separate translation reactions. The products were then incubated
together, followed by immunoprecipitation with an anti-Nrf2
antibody, and the precipitated products were subjected to SDS-PAGE and
autoradiography. Keap1 could be quantitatively co-precipitated with
Nrf2 by the anti-Nrf2 antibody (Fig.
6A).
We then investigated the interaction between Keap1 and the
Nrf2-S40A mutant. Similar amounts of Keap1 co-precipitated with both wild-type and S40A Nrf2 (Fig. 6B). However, when
immunoprecipitation was carried out after incubation of these
components in the presence of PKC, the amount of Keap1 associated with
wild-type Nrf2 was reduced by about 50%. By contrast, the S40A
mutant interacted with Keap1 to a similar extent with or without PKC
(Fig. 6B). Furthermore, the dissociation of Keap1 from
wild-type Nrf2 was abolished when PKC was preincubated in the
presence of 10 nM staurosporine, a potent inhibitor of PKC
(not shown). We therefore conclude that phosphorylation of Nrf2
by PKC at Ser-40 plays a critical role in facilitating the release of
Nrf2 from Keap1. Consequently, the impaired ability of the
Nrf2-S40A mutant to activate ARE-mediated transcription is most
likely due to a defect in the dissociation of Nrf2 from its
cytoplasmic inhibitor Keap1.
We recently reported that phosphorylation of Nrf2 by PKC
induces nuclear translocation of this transcription factor and
activation of the ARE in response to oxidative stress (23). In the
present study, we further characterized the molecular mechanisms of
Nrf2 phosphorylation and its functional significance in ARE
activation. Our data demonstrate that PKC phosphorylates Nrf2 at
Ser-40 and facilitates its release from the cytoplasmic anchor Keap1.
Together with our earlier findings, these results suggest a mechanistic model of ARE-mediated cellular antioxidant response involving the
PKC-catalyzed phosphorylation of Nrf2 at Ser-40 as a specific trigger for the nuclear translocation of this transcription factor.
Previous studies from Itoh et al. (12) using cell-based
overexpression systems demonstrated that Nrf2 is normally
retained in the cytoplasm by its association with the
cytoskeleton-binding protein Keap1. Electrophilic agents liberate
Nrf2 from the Nrf2-Keap1 cytosolic complex, allowing it
to traverse into the nucleus to activate ARE-driven gene expression.
Deletion mapping experiments further indicated that Keap1 binds through
the Neh2 domain of Nrf2, comprising ~100 N-terminal amino
acids (12). Our in vitro results here provide a mechanistic
explanation for the importance of this domain in Nrf2-Keap1
interaction. A critical residue within this region appears to be
Ser-40, whose phosphorylation by PKC upon oxidative stress promotes the
dissociation of Nrf2 from Keap1. It remains to be tested in
intact cells whether Ser-40 phosphorylation is sufficient or whether
other molecular events and components must also be involved for
Nrf2 to disengage from its cytoplasmic inhibitor and translocate
into the nucleus. It is also not known whether Keap1 itself is a PKC
target. Rat Keap1 possesses five potential PKC sites, four within the
KELCH and C-terminal regions, which have been identified as important
for binding to Nrf2 (13). However, because we did not observe a
reduction in the amount of Keap1 co-precipitated with the
Nrf2-S40A mutant upon incubation with PKC, apparently no
PKC-induced alterations occurred on Keap1 that would weaken the
Keap1-Nrf2 interaction in vitro.
The present findings suggest that the functional significance of PKC
phosphorylation of Nrf2 is likely to involve specifically the
nuclear cytoplasmic shuttling step. The defect exhibited by the
Nrf2-S40A mutant in ARE-driven reporter gene assay appears to
correlate with the amount of the available cytoplasmic inhibitor Keap1.
Thus the repression of ARE-mediated gene expression by overexpression
of Keap1 became more pronounced in the presence of Nrf2-S40A,
presumably due to the dissociation defect of this mutant. However, the
formation of ARE-binding complex with Nrf2/MafK in the gel shift
assay was not affected by the state of PKC-catalyzed phosphorylation of
Nrf2 or when the S40A mutant was used. Therefore PKC
phosphorylation does not appear to play a role in either the association of Nrf2/MafK heterodimer with the ARE sequence or dimerization of Nrf2 with MafK. PKC has also been implicated in the aryl hydrocarbon receptor-mediated transcriptional regulation (26,
27). Although PKC action in that pathway appears to involve a nuclear
event, it does not impact the DNA-binding activity of the transcription
factor (26). It will be interesting to determine whether the
Nrf2 proteins present in the nucleus are predominantly of the
phosphorylated form, even though phosphorylation by PKC does not seem
to be required for high affinity binding of Nrf2 to the ARE. The
simplest model based upon our results would suggest that
phospho-Nrf2, after release from Keap1, is directly transported into the nucleus for binding to the ARE sequence. However, it is
possible that yet unidentified protein phosphatases act before the
binding of Nrf2 to its target sequence and promote the export of
this transcription factor back into the cytoplasm as part of a
regulatory cycle of phosphorylation-dependent nuclear
cytoplasmic shuttling of Nrf2. In studies of other systems,
oxidants have been shown to activate kinases and inactivate
phosphatases in concert (28).
Our prior studies suggesting the involvement of PKC in ARE activation
by Nrf2 were performed with pharmacological inhibitors of PKC
such as staurosporine. In identifying a site-specific mutant (S40A)
that abrogates PKC-catalyzed phosphorylation of Nrf2 and impairs
its dissociation from Keap1, we have confirmed an essential role for
PKC phosphorylation of Nrf2 in the signaling pathway leading to
ARE activation. The present results support a direct role for PKC,
rather than its downstream kinases, in the regulation of Nrf2
activity. An important question is whether PKC itself may be a sensor
for oxidative stress. An early report showed that catechol and
hydroquinone, which are potent inducers of the ARE, also activate PKC
(29). PKC possesses structural features that suggest it as an excellent
target for direct redox-sensitive modifications (30). Indeed there have
been several reports indicating oxidation of reactive cysteines in both
its N-terminal regulatory and C-terminal catalytic domains that serves
to regulate PKC activity (30). Although it is at present unclear what
isoform(s) of PKC phosphorylates Nrf2, a likely candidate may be
PKC Reports from several laboratories have indicated the involvement of
other kinase pathways in ARE-mediated transcription (17-22). Transfection studies using wild-type and dominant-negative MAPK and
Nrf2 have suggested a positive role for MAPK in ARE regulation in HepG2 cells (15, 16). However, inhibition of ERK in H4IIE cells
resulted in increased expression of the GSTA2 gene,
suggesting a negative role for ERK in ARE-mediated activity (18). The
exact role of the p38 kinase in ARE regulation is also confusing from existing literature, as several laboratories have reported a positive effect (17, 19, 20) whereas another showed that a p38 inhibitor caused
the activation of ARE-dependent reporter gene (21).
Recently, PI 3-kinase and its downstream Akt kinase have been shown by
inhibitor studies to be positive regulators of ARE activity in H4IIE
hepatoma (18) and IMR-32 neuroblastoma cells (22). Further elucidation of the precise roles of these kinases will be facilitated by the identification of specific cellular targets known to be involved in ARE
regulation. It should be noted that in IMR-32 cells, ARE-mediated transcription has been reported to be PKC-independent (33). However,
the same experimental system was also shown to be oxidative stress-independent, in contrast to the many studies from hepatocytes where oxidative stress-induced ARE-mediated gene expression has been
firmly established.
Although the EMSA results indicate that Nrf2/MafK interaction
with ARE is independent of PKC phosphorylation, it remains possible that binding of Nrf2 with a nuclear factor other than small Maf proteins to the ARE may be subjected to regulation by PKC. Our earlier
studies have suggested that such alternative factors may exist, as
nuclear extract from HepG2 and H4IIEC3 cells formed complexes with the
ARE that are distinct from those formed by in vitro
translated Nrf2/MafK proteins (24). There have been several
reports of alternative Nrf2 partners binding to the ARE (34-37). CBP (cAMP-responsive element-binding protein) has recently been shown to bind Nrf2 via two transactivation domains on
Nrf2 in a cooperative manner to activate ARE transcription
synergistically (36). ATF4 has also been demonstrated to interact with
Nrf2 in regulating ARE-driven heme oxygenase-1 gene expression
(37).
It should be noted that although the nuclear translocation of
Nrf2 has been shown to be a major mechanism for ARE activation in all cell types examined, Nrf2 also has a documented role in constitutive ARE-mediated gene expression. We have shown that Nrf2 is present in the nucleus without tBHQ stimulation, and its essential role in mediating the basal activity of the ARE has been
reported in a cell-free system (24) and in nrf2-null
mice (11). Future investigations should reveal molecular details that
comprise the coordinated transcriptional activation of antioxidant enzymes, of which phosphorylation of Nrf2 at Ser-40 by PKC is but one of many critical regulatory steps.
We thank Dr. Philip Sherratt for useful advice
and discussions.
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Published, JBC Papers in Press, August 26, 2002, DOI 10.1074/jbc.M206911200
The abbreviations used are:
ARE, antioxidant
response element;
Nrf2, NF-E2-related factor 2;
PKC, protein
kinase C;
MAP kinase, mitogen-activated protein kinase;
ERK1/2, extracellular signal-regulated kinase;
PI 3-kinase, phosphatidylinositol 3-kinase;
PMA, phorbol 12-myristate 13-acetate;
tBHQ, tert-butylhydroquinone;
QR, NAD(P)H:quinone
oxidoreductase;
CAT, chloramphenicol acetyltransferase;
EMSA, electrophoretic mobility shift assay;
Ni-NTA, nickel-nitrilotriacetic
acid;
WT, wild type.
Phosphorylation of Nrf2 at Ser-40 by Protein Kinase C
Regulates Antioxidant Response Element-mediated Transcription*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
GCT) was obtained by the PCR
mutagenesis method and cloned into the same expression plasmid.
Nrf2 wild-type or S40A mutant expression was induced by the
addition of 0.5 mM
isopropyl-
-D-thiogalactopyranoside for 6 h at
30 °C in Escherichia coli M15 cells. Cell pellets were suspended and sonicated in a buffer containing 100 mM
NaH2PO4, 10 mM Tris-HCl (pH 8.0),
300 mM NaCl, 0.1 mM EDTA, 5 mM
-mercaptoethanol, 10 mM imidazole, 0.5% Tween 20, and
15% glycerol. After centrifugation at 14,000 × g for
20 min, soluble lysates were loaded onto a Ni-NTA column. A 40 mM imidazole wash was followed by elution at 250 mM imidazole in the same buffer. Eluted fractions were
pooled and dialyzed against 20 mM HEPES (pH 7.5), 200 mM NaCl, 0.1 mM EDTA, 1 mM
dithiothreitol, and 20% glycerol and stored at
80 °C.
-33P]ATP and stopped at the indicated times by the
addition of sample buffer for SDS-PAGE analysis. The level of
[33P]ATP incorporation into Nrf2 was determined by
autoradiography or by a PhosphorImager (Fujifilm FLA-2000).
[
-33P]ATP was omitted from kinase reactions whose
products were subsequently used in electrophoretic mobility shift
assays (EMSA) or in immunoprecipitation studies as described below.
-32P]ATP by T4 polynucleotide kinase. The sequence of
the DNA probe was
5'-GATTTCAGTCTAGAGTCACAGTGACTTGGCAAAATCTGAGCCG-3' (ARE core
sequence highlighted in bold). Purified rat Nrf2 wild-type or
S40A mutant protein was preincubated with rat MafK (unless otherwise
indicated) for 20 min at 25 °C before the addition of DNA probe for
another 20 min at 30 °C. MafK proteins were produced in
vitro by the TNT coupled transcription/translation
wheat germ extract system (Promega) (24). DNA-protein interactions were detected by electrophoresis on non-denaturing 6% polyacrylamide gels in Tris borate-EDTA (TBE) buffer, followed by autoradiography. For
competition experiments, a 200-fold molar excess of either unlabeled
probe or a random 43-base oligonucleotide was included in the
preincubation mixture at 25 °C before the addition of the labeled
probe. For supershift assay, an anti-Nrf2 antibody (sc-722X; Santa Cruz Biotechnology) was added after the binding reaction for
4 h at 4 °C before electrophoresis. To determine the effect of
PKC phosphorylation of Nrf2 on ARE binding, Nrf2
wild-type or S40A mutant protein was first incubated in kinase assay
buffer for 1 h at 30 °C in the presence or absence of PKC,
before an aliquot was taken for incubation with MafK and the labeled
probe for EMSA.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (60K):
[in a new window]
Fig. 1.
Peptide inhibition of Nrf2
phosphorylation by PKC. A, amino acid sequence of rat
Nrf2. Seven potential PKC phosphorylation sites
((S/T)X(R/K)) are shown in
bold. Synthetic peptides used to mimic these sites are
underlined. B, in vitro kinase assays
were performed using 2 µM purified Nrf2, 5 nM catalytic subunit of rat brain PKC, 2 µCi of
[
-33P]ATP in the presence of 5 mM of the
indicated peptides for 20 min at 30 °C. 33P-Labeled
Nrf2 was resolved by SDS-PAGE and subjected to
autoradiography.
GCT (Ser to Ala)
mutation at amino acid position 40 (nrf2-S40A) was cloned into a high level expression plasmid containing a
His6-tag N-terminal to the insert. E. coli-expressed Nrf2-S40A protein was purified to near
homogeneity by metal chelate affinity chromatography (Fig.
2). The prominent band at ~90 kDa was
confirmed to be Nrf2 by Western blot using an antibody against
Nrf2 (not shown). Nrf2-S40A was then used in parallel
with wild-type Nrf2 as substrates in in vitro PKC
assays. As shown in Fig. 3, the single
amino acid change from Ser to Ala at position 40 completely abolished
PKC phosphorylation of Nrf2. The lack of residual
phosphorylation in this mutant indicates that Ser-40 is the only PKC
site, consistent with the peptide competition data.

View larger version (34K):
[in a new window]
Fig. 2.
Expression and purification of
His6-tagged Nrf2-S40A protein.
Nrf2-S40A (AGT
GCT) mutant was cloned into pQE30 expression
vector (Qiagen). Nrf2-S40A fusion protein containing a
His6 tag at the N terminus was overexpressed in E. coli upon induction for 6 h at 30 °C in the presence of
0.5 mM isopropyl-
-D-thiogalactopyranoside,
and purified by Ni-NTA affinity chromatography. Coomassie Brilliant
Blue G-250 stain of samples resolved by SDS-PAGE is shown: total lysate
before (lane 1) and after (lane 2) IPTG
induction, soluble lysate loaded on a Ni-NTA column (lane
3), Ni-NTA column flow-through (lane 4), 40 mM imidazole wash (lane 5), 250 mM
imidazole elution (lane 6). Protein band indicated by the
arrow was confirmed to be Nrf2 by Western blot with
an anti-Nrf2 antibody (not shown).

View larger version (34K):
[in a new window]
Fig. 3.
PKC phosphorylates Nrf2 at
Ser-40. PKC activity was assayed as in Fig. 1B using 2 µM purified wild-type Nrf2 or Nrf2-S40A
mutant protein as substrate for the indicated times at 30 °C.
Western blot using an anti-Nrf2 antibody was performed for an
aliquot of the same samples as those shown in the autoradiogram
above.

View larger version (36K):
[in a new window]
Fig. 4.
Binding of Nrf2/MafK to the ARE is
PKC-independent. EMSAs were performed as described under
"Experimental Procedures" using 32P-labeled rat
QR ARE sequence as probe. His6-Nrf2
wild-type (WT) and S40A proteins were purified from E. coli as described in Fig. 2. In vitro
transcribed/translated MafK proteins were produced from TNT
coupled wheat germ extract system (Promega). A, supershift
analysis was carried out by adding an anti-Nrf2 antibody to the
incubation mixture for 4 h at 4 °C prior to electrophoresis.
B, competition experiments were performed in the presence of
200-fold molar excess of unlabeled oligonucleotides containing the rat
QR ARE or a random sequence. C, EMSA was preceded
by incubating Nrf2 wild-type and S40A proteins for 1 h at
30 °C in a PKC kinase assay buffer with or without PKC.

View larger version (39K):
[in a new window]
Fig. 5.
Defective ARE activation by Nrf2-S40A
involves Keap1. Rat QR ARE-CAT reporter construct (1 µg) was co-transfected with pcDNA3 expression plasmid (0.12 µg)
bearing wild-type or S40A Nrf2 into HepG2 cells on 6-well tissue
culture plates. Where indicated, 60 ng of Keap1-pcDNA3 plasmid was
co-transfected. CAT assays were performed as previously described, and
the results were quantitated by a PhosphorImager. Activity is shown as
-fold activation over the level obtained with transfection of an empty
pcDNA3 vector in the absence of Keap1 plasmid. The data represent
means of three independent experiments.

View larger version (22K):
[in a new window]
Fig. 6.
PKC-dependent interaction between
Nrf2 and Keap1. A, Nrf2 (wild-type) and
Keap1 were in vitro transcribed and translated in the
presence of [35S]methionine and incubated together where
indicated for 15 min at 30 °C before immunoprecipitation by an
antibody against Nrf2. The amount of Keap1 used in incubation
with Nrf2 was doubled in the last lane. Precipitated products
were washed, resolved by SDS-PAGE, and autoradiographed. B,
similar immunoprecipitation experiments as in A were
performed using wild-type or S40A Nrf2 and Keap1. A 30-min
incubation of Nrf2 and Keap1 at 30 °C in a PKC assay buffer
in the presence or absence of PKC preceded immunoprecipitation. Band
intensity was quantified by a PhosphorImager. The amounts of
Nrf2 precipitated were normalized, and the amount of Keap1 that
co-precipitated under each condition was expressed relative to that
co-precipitated with Nrf2-WT without PKC (set as 100). The
results shown are typical of at least three separate experiments.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
, which has been implicated in a number of cellular processes
involving oxidative stress (31, 32).
![]()
ACKNOWLEDGEMENT
![]()
FOOTNOTES
To whom correspondence should be addressed: Schering-Plough
Research Institute, 2015 Galloping Hill Rd., Kenilworth, NJ 07033. Tel.: 908-740-7300; Fax: 908-740-7514; E-mail:
cecil.pickett@spcorp.com.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Rushmore, T. H.,
and Pickett, C. B.
(1990)
J. Biol. Chem.
265,
14648-14653 2.
Friling, R. S.,
Bensimon, A.,
Tichauer, Y.,
and Daniel, V.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
6258-6262 3.
Favreau, L. V.,
and Pickett, C. B.
(1991)
J. Biol. Chem.
266,
4556-4561 4.
Li, Y.,
and Jaiswal, A. K.
(1992)
J. Biol. Chem.
267,
15097-15104 5.
Wild, A. C.,
Moinova, H. R.,
and Mulcahy, R. T.
(1999)
J. Biol. Chem.
274,
33627-33636 6.
Alam, J.,
Stewart, D.,
Touchard, C.,
Boinapally, S.,
Choi, A. M. K.,
and Cook, J. L.
(1999)
J. Biol. Chem.
274,
26071-26078 7.
Moi, P,
Chan, K.,
Asunis, I.,
Cao, A.,
and Kan, Y. W.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
9926-9930 8.
Igarashi, K.,
Kataoka, K.,
Itoh, K.,
Hayashi, N.,
Nishizawa, M.,
and Yamamoto, M.
(1994)
Nature (Lond.)
367,
568-572[CrossRef][Medline]
[Order article via Infotrieve]
9.
Itoh, K.,
Chiba, T.,
Takahashi, S.,
Ishii, T.,
Igarashi, K.,
Katoh, Y.,
Oyake, T.,
Hayashi, N.,
Satoh, K.,
Hatayama, I.,
Yamamoto, M.,
and Nabeshima, Y.
(1997)
Biochem. Biophys. Res. Commun.
236,
313-322[CrossRef][Medline]
[Order article via Infotrieve]
10.
Kwak, M. K.,
Itoh, K.,
Yamamoto, M.,
Sutter, T. R.,
and Kensler, T. W.
(2001)
Mol. Med.
7,
135-145[Medline]
[Order article via Infotrieve]
11.
McMahon, M.,
Itoh, K.,
Yamamoto, M.,
Chanas, S. A.,
Henderson, C. J.,
McLellan, L. I.,
Wolf, C. R.,
Cavin, C.,
and Hayes, J. D.
(2001)
Cancer Res.
61,
3299-3307 12.
Itoh, K.,
Wakabayashi, N.,
Katoh, Y.,
Ishii, T.,
Igarashi, K.,
Engel, J. D.,
and Yamamoto, M.
(1999)
Genes Dev.
13,
76-86 13.
Dhakshinamoorthy, S.,
and Jaiswal, A. K.
(2001)
Oncogene
20,
3906-3917[CrossRef][Medline]
[Order article via Infotrieve]
14.
Sekhar, K. R.,
Spitz, D. R.,
Harris, S.,
Nguyen, T. T.,
Meredith, M. J.,
Holt, J. T.,
Guis, D.,
Marnett, L. J.,
Summar, M. L.,
and Freeman, M. L.
(2002)
Free Rad. Biol. Med.
32,
650-662[CrossRef][Medline]
[Order article via Infotrieve]
15.
Yu, R.,
Lei, W.,
Mandlekar, S.,
Weber, M. J.,
Der, C. J., Wu, J.,
and Kong, A.-N. T.
(1999)
J. Biol. Chem.
274,
27545-27552 16.
Yu, R.,
Chen, C., Mo, Y. Y.,
Hebbar, V.,
Owuor, E. D.,
Tan, T.-H.,
and Kong, A.-N. T.
(2000)
J. Biol. Chem.
275,
39907-39913 17.
Zipper, L. M.,
and Mulcahy, R. T.
(2000)
Biochem. Biophys. Res. Commun.
278,
484-492[CrossRef][Medline]
[Order article via Infotrieve]
18.
Kang, K. W.,
Cho, M. K.,
Lee, C. H.,
and Kim, S. G.
(2001)
Mol. Pharmacol.
59,
1147-1156 19.
Kang, K. W.,
Ryu, J. H.,
and Kim, S. G.
(2000)
Mol. Pharmacol.
58,
1017-1025 20.
Alam, J.,
Wicks, C.,
Stewart, D.,
Gong, P.,
Touchard, C.,
Otterbein, S.,
Choi, A. M.,
Burow, M. E.,
and Tou, J.
(2000)
J. Biol. Chem.
275,
27694-27702 21.
Yu, R.,
Mandlekar, S.,
Lei, W.,
Fahl, W. E.,
Tan, T.-H.,
and Kong, A.-N. T.
(2000)
J. Biol. Chem.
275,
2322-2327 22.
Lee, J.-M.,
Hanson, J. M.,
Chu, W. A.,
and Johnson, J. A.
(2001)
J. Biol. Chem.
276,
20011-20016 23.
Huang, H.-C.,
Nguyen, T.,
and Pickett, C. B.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
12475-12480 24.
Nguyen, T.,
Huang, H.-C.,
and Pickett, C. B.
(2000)
J. Biol. Chem.
275,
15466-15473 25.
Dhakshinamoorthy, S.,
and Jaiswal, A. K.
(2000)
J. Biol. Chem.
275,
40134-40141 26.
Chen, Y.-H.,
and Tukey, R. H.
(1996)
J. Biol. Chem.
271,
26261-26266 27.
Long, W. P.,
Chen, X.,
and Perdew, G. H.
(1999)
J. Biol. Chem.
274,
12391-12400 28.
Meng, T. C.,
Fukada, T.,
and Tonks, N. K.
(2002)
Mol. Cell
9,
387-399[CrossRef][Medline]
[Order article via Infotrieve]
29.
Gopalakrishna, R.,
Chen, Z.-H.,
and Gundimeda, U.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
12233-12237 30.
Gopalakrishna, R.,
and Jaken, S.
(2000)
Free Rad. Biol. Med.
28,
1349-1361[CrossRef][Medline]
[Order article via Infotrieve]
31.
Jain, N.,
Zhang, T.,
Kee, W. H., Li, W.,
and Cao, X.
(1999)
J. Biol. Chem.
274,
24392-24400 32.
Sun, X., Wu, F.,
Datta, R.,
Kharbanda, S.,
and Kufe, D.
(2000)
J. Biol. Chem.
275,
7470-7473 33.
Lee, J.-M.,
Moehlenkamp, J. D.,
Hanson, J. M.,
and Johnson, J. A.
(2001)
Biochem. Biophys. Res. Commun.
280,
286-292[CrossRef][Medline]
[Order article via Infotrieve]
34.
Montano, M. M.,
Wittmann, B. M.,
and Bianco, N. R.
(2000)
J. Biol. Chem.
275,
34306-34313 35.
Zhu, M.,
and Fahl, W. E.
(2001)
Biochem. Biophys. Res. Commun.
289,
212-219[CrossRef][Medline]
[Order article via Infotrieve]
36.
Katoh, Y.,
Itoh, K.,
Yoshida, E.,
Miyagishi, M.,
Fukamizu, A.,
and Yamamoto, M.
(2001)
Genes Cells
6,
857-868[Abstract]
37.
He, C. H.,
Gong, P., Hu, B.,
Stewart, D.,
Choi, M. E.,
Choi, A. M.,
and Alam, J.
(2001)
J. Biol. Chem.
276,
20858-20865
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
A. K. Jain, S. Mahajan, and A. K. Jaiswal Phosphorylation and Dephosphorylation of Tyrosine 141 Regulate Stability and Degradation of INrf2: A NOVEL MECHANISM IN NRF2 ACTIVATION J. Biol. Chem., June 20, 2008; 283(25): 17712 - 17720. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Theodore, Y. Kawai, J. Yang, Y. Kleshchenko, S. P. Reddy, F. Villalta, and I. J. Arinze Multiple Nuclear Localization Signals Function in the Nuclear Import of the Transcription Factor Nrf2 J. Biol. Chem., April 4, 2008; 283(14): 8984 - 8994. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Sibhatu, P. K. Smitherman, A. J. Townsend, and C. S. Morrow Expression of MRP1 and GSTP1-1 modulate the acute cellular response to treatment with the chemopreventive isothiocyanate, sulforaphane Carcinogenesis, April 1, 2008; 29(4): 807 - 815. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhu, J. Pi, S. Wachi, M. E. Andersen, R. Wu, and Y. Chen Identification of Nrf2-dependent airway epithelial adaptive response to proinflammatory oxidant-hypochlorous acid challenge by transcription profiling Am J Physiol Lung Cell Mol Physiol, March 1, 2008; 294(3): L469 - L477. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Brown, K. R. Sekhar, G. Rachakonda, S. Sasi, and M. L. Freeman Activating Transcription Factor 3 Is a Novel Repressor of the Nuclear Factor Erythroid-Derived 2 Related Factor 2 (Nrf2) Regulated Stress Pathway Cancer Res., January 15, 2008; 68(2): 364 - 368. [Abstract] [Full Text] [PDF] |
||||
![]() |
O.-H. Lee, A. K. Jain, V. Papusha, and A. K. Jaiswal An Auto-regulatory Loop between Stress Sensors INrf2 and Nrf2 Controls Their Cellular Abundance J. Biol. Chem., December 14, 2007; 282(50): 36412 - 36420. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-Y. Park, X. Yu, C. Ip, J. L. Mohler, P. N. Bogner, and Y.-M. Park Peroxiredoxin 1 Interacts with Androgen Receptor and Enhances Its Transactivation Cancer Res., October 1, 2007; 67(19): 9294 - 9303. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Purdom-Dickinson, E. V. Sheveleva, H. Sun, and Q. M. Chen Translational Control of Nrf2 Protein in Activation of Antioxidant Response by Oxidants Mol. Pharmacol., October 1, 2007; 72(4): 1074 - 1081. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-H. Li, J.-H. Jang, H.-K. Na, Y.-N. Cha, and Y.-J. Surh Carbon Monoxide Produced by Heme Oxygenase-1 in Response to Nitrosative Stress Induces Expression of Glutamate-Cysteine Ligase in PC12 Cells via Activation of Phosphatidylinositol 3-Kinase and Nrf2 Signaling J. Biol. Chem., September 28, 2007; 282(39): 28577 - 28586. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Dai, S. Vaughn, Y. Zhang, E. T. Wang, G. Garcia-Cardena, and M. A. Gimbrone Jr Biomechanical Forces in Atherosclerosis-Resistant Vascular Regions Regulate Endothelial Redox Balance via Phosphoinositol 3-Kinase/Akt-Dependent Activation of Nrf2 Circ. Res., September 28, 2007; 101(7): 723 - 733. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Cho, W. D. Kim, S. H. Ki, J.-I. Hwang, S. Choi, C. H. Lee, and S. G. Kim Role of G{alpha}12 and G{alpha}13 as Novel Switches for the Activity of Nrf2, a Key Antioxidative Transcription Factor Mol. Cell. Biol., September 1, 2007; 27(17): 6195 - 6208. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Jain and A. K. Jaiswal GSK-3beta Acts Upstream of Fyn Kinase in Regulation of Nuclear Export and Degradation of NF-E2 Related Factor 2 J. Biol. Chem., June 1, 2007; 282(22): 16502 - 16510. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Kim and S. J. Lee PI3K, RSK, and mTOR Signal Networks for the GST Gene Regulation Toxicol. Sci., April 1, 2007; 96(2): 206 - 213. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liu, J. T. Kern, J. R. Walker, J. A. Johnson, P. G. Schultz, and H. Luesch A genomic screen for activators of the antioxidant response element PNAS, March 20, 2007; 104(12): 5205 - 5210. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Cavin, T. Delatour, M. Marin-Kuan, D. Holzhauser, L. Higgins, C. Bezencon, G. Guignard, S. Junod, J. Richoz-Payot, E. Gremaud, et al. Reduction in Antioxidant Defenses may Contribute to Ochratoxin A Toxicity and Carcinogenicity Toxicol. Sci., March 1, 2007; 96(1): 30 - 39. [Abstract] [Full Text] [PDF] |
||||